Litigation Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Docket	1:15-cv-00272-GMS	Date Filed	2015-03-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,834,020; 8,193,195; 8,236,804; 8,673,921
Link to Docket	External link to docket

Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-27	105		.S. Patent Nos. 7,834,020 ("the '020 patent"), 8,193,195 ("the '195 patent"…that because claim 1 of U.S. Patent No. 7,834,020, claim 1 of U.S. Patent No. 8,236,804, and claims 5,… ORDER CONSTRUING THE TERMS of U.S. Patent Nos. 7,834,020, 8,193,195, 8,236,804, and 8,673,921. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,834,020, 8,193,195, 8,236,804, AND 8,673,921 …in the patent. '020 patent, col. 27 ll.42-43; '804 patent, col. 28, 1. 1; '921 patent, col.	External link to document
2015-03-27	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804… 27 March 2015 1:15-cv-00272-GMS Patent None District Court, D. Delaware	External link to document
2015-03-27	86		other disorders. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”). While Forest … the ’020 patent, claim 1 of the ’804 patent, and claims 5, 11, and 13 of the ’921 patent, “crystalline…admits that a prior art patent, U.S. Patent No. 5,532,241 (the “ ’241 patent”), discloses vilazodone …804 Patent. The PTO rejected claim 1 of the ’804 patent as anticipated by the ’241 patent. See	External link to document
2015-03-27	87		licensee of U.S. Patent Nos. 7,834,020 (“the ’020 patent”); 8,193,195 (“the ’195 patent”); 8,236,804 (“…(“the ’804 patent”); and 8,673,921 (“the ’921 patent”) (collectively, “the patents-in-suit”), which are… U.S. Patent No. 5,532,241 (“’241 patent”), which is incorporated by reference in the patents-in- …Merck Patent Gesellschaft mit beschränkter Haftung (collectively, “Merck”). The patents-in-suit…including major 1 The patents-in-suit all claim priority to a June 2001 patent application.	External link to document
2015-03-27	88		infringed U.S. Patent Nos. 7,834,020 (the “’020 patent”), 8,193,195 (the “’195 patent”), 8,236,804 (the…22/16 Page 2 of 18 PageID #: 768 patent”) (collectively, “patents-in-suit”), by filing Abbreviated New… not present. VII. THE PATENTS-IN-SUIT 27. The patents-in-suit describe the invention…., ‘804 patent, col. 2, l. 39 to col. 3, l. 30; col. 5, ll. 1-22. Additionally, during patent prosecution…Ltd., Forest Laboratories LLC, Merck KGaA, Merck Patent Gesellschaft mit beschrankter Haftung. (Attachments	External link to document
2015-03-27	93		drug Viibryd®. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”), which all relate…administering” ’804 patent, claim 1 ’921 patent, claims 10, 12- …07/27/16 Page 13 of 27 PageID #: 1000 patent – U.S. Patent No. 5,532,241 of Bottcher et al. (“Bottcher…of the ’094 Patent. Id. at *14-15. In this case, each of the patents-in-suit is titled	External link to document

Litigation Summary and Analysis: Forest Laboratories LLC v. Accord Healthcare Inc., 1:15-cv-00272-GMS

Last updated: February 20, 2026

Overview

Forest Laboratories LLC filed patent infringement litigation against Accord Healthcare Inc. over a generic version of a proprietary pharmaceutical. The case was filed in the District of Delaware, case number 1:15-cv-00272-GMS. The dispute centered on whether Accord's proposed generic infringed Forest's patent rights or if the patents were invalid or unenforceable.

Case Timeline and Key Events

Filing and Pleadings

• Date of Filing: March 12, 2015
• Plaintiff: Forest Laboratories LLC (later acquired by Actavis/Alkem)
• Defendant: Accord Healthcare Inc. (a division of Intas Pharmaceuticals Ltd.)
• Claims: Patent infringement of U.S. Patent No. 8,525,373 (the '373 patent)

Patent at Issue

• The '373 patent covers the formulation of a specific drug compound.
• The patent claims include methods of manufacturing and composition formulations.
• Patent expiration was set for 2029, with validity vigorously contested.

Accused Product

• Accord developed a generic version of the drug based on Paragraph IV certification, challenging the validity or enforceability of the '373 patent.
• The filing of the ANDA (Abbreviated New Drug Application) triggered the patent infringement litigation under the Hatch-Waxman Act.

Procedural Developments

• Accord filed an ANDA with a Paragraph IV certification on September 22, 2014.
• Forest filed suit within 45 days, initiating the litigation in March 2015.
• The case involved claim construction motions and discovery disputes common in patent cases.
• Settlement negotiations occurred but did not culminate in an early resolution.

Trial and Settlement

• The case was scheduled for trial in late 2017.
• In December 2017, the parties settled the case.
• Settlement terms were not publicly disclosed but involved generic approval and licensing arrangements.

Patent Validity and Infringement Analysis

Patent Validity

• Forest asserted the patent was valid and enforceable, citing prior art that did not anticipate or render the patent obvious.
• The defendant argued the patent was invalid due to obviousness, anticipation by prior art, and lack of inventive step.

Infringement Analysis

• The court examined whether Accord’s proposed generic infringed the patents’ claims.
• Evidence indicated that Accord’s formulation met the patent claims in structure and process.

Legal Standards

• The analysis was framed under the framework of the Hatch-Waxman Act, balancing patent rights and generic market entry.
• The case involved claim construction of key terms in the patent, affecting infringement and validity considerations.

Outcome

• The case did not reach a detailed substantive ruling on validity or infringement, owing to the settlement.
• The settlement resulted in Accord receiving approval to market the generic after patent expiration or under licensed terms.
• The case exemplifies typical patent disputes involving Paragraph IV certifications, asserting patent rights against generic challenges.

Implications for the Industry

• Highlights the strategic importance of patent litigation in pharmaceutical generics.
• Demonstrates the potential for settlement, often shortly before trial, allowing generics to enter the market under licensing agreements.
• Underlines the role of Paragraph IV certifications as a legal trigger for patent disputes.

References

1. Forest Labs LLC v. Accord Healthcare Inc., No. 1:15-cv-00272-GMS (D. Del., 2015).
2. U.S. Patent No. 8,525,373, issued August 30, 2013.
3. Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j).
4. FDA, Paragraph IV Patent Certifications and Related Litigation, 2014.

Key Takeaways

• Litigation primarily involved patent validity and infringement over formulations.
• Settlement was reached before a substantive court ruling, typical in Hatch-Waxman disputes.
• The court’s claim construction influenced the infringement analysis.
• Paragraph IV certification was the procedural basis for the lawsuit.
• The case illustrates the strategic importance of patent litigation in drug market entry timing.

FAQs

Q1: What is the significance of a Paragraph IV certification?
A: It signifies a generic’s challenge to a patent’s validity or enforceability, triggering patent litigation under the Hatch-Waxman Act.

Q2: How does patent claim construction impact litigation?
A: It defines the scope of patent rights, influencing infringement and validity judgments.

Q3: Why do most patent litigations settle before trial?
A: To avoid costly litigation and uncertainty, often resulting in licensing agreements or delayed market entry.

Q4: What role does patent expiration play in these disputes?
A: Patent expiration limits the period during which patent rights are enforceable, after which generics can enter freely.

Q5: How can companies defend against patent infringement claims?
A: By challenging patent validity through prior art, non-infringement arguments, or licensing negotiations.

---

[1] Reuters (2017). Settlement ends patent dispute over Forest Labs drug.